Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 742-746DOI: 10.1055/s-0038-1657622 Newer antithrombotic agents Schattauer GmbH Stuttgart Thrombolytic Therapy Désiré Collen The Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (1042 kb) References References 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124 2 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?. Blood 1994; 84: 680-686 3 LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766 4 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682 5 Collen D. Coronary thrombolysis:streptokinase or recombinant tissue-type plasminogen activator?. Ann Intern Med 1990; 112: 529-538 6 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622 7 Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-36 8 Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110 9 Madison EL. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994; 8: 221-236 10 International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995; 346: 329-336 11 Kawai C, Hosoda S, Motomiya T. et al, for the E6010 Investigators. Multicenter trial of a novel modified t-PA, E6010, by i.v. bolus injection in patients with acute myocardial infarction (AMI). Circulation 1992; 86: 001-409 (Abstract 1630). 12 Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674 13 Collen D, Stassen JM, Yasuda T, Refino CJ, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72: 098-104 14 Cannon CP, McCabe CH, Gibson CM. et al. TNK-tissue plasminogen activator in acute myocardial infarction:results of the Thrombolysis in Myocardial Infarction (TIMI) lOAdose ranging trial. Circulation 1997; 95: 351-356 15 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jari D, Wang SP, Tung JS, Mark GE. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253 16 Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-426 17 Haber E. Antibody targeting:a strategy for improving thrombolytic therapy. In: Molecular Cardiovascular Medicine. Haber E. ed. Scientific America; New York, NY: 1995. pp 145-155 18 Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasminogen and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271: 27912-27918 19 Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De ManF, Benit E, Muyldermans L, Collen D, Van de WerfF. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049 20 Collen D, Zhao ZA, Holvoet P, Marijnen P. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992; 06: 226-231 21 Collen D, Bernaerts R, Declerck PJ, De CockF, Demarsin E, Jenné S, Laroche Y, Lijnen HR, Silence K, Verstreken M. Recombinant staphylokinase variants with altered immunore-activity, I:Construction and characterization. Circulation 1996; 94: 197-206 22 Collen D, Moreau H, Stockx L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity, II:thrombolytic properties and antibody induction. Circulation 1996; 94: 207-216 23 Schlant (Chairman) RC. Reperfusion in acute myocardial infarction. Circulation 1994; 90: 2091-2102
